WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2003006023) PYRAZINONE INHIBITORS OF FATTY ACID BINDING PROTEIN AND METHOD
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2003/006023    International Application No.:    PCT/US2002/022186
Publication Date: 23.01.2003 International Filing Date: 12.07.2002
Chapter 2 Demand Filed:    12.02.2003    
IPC:
B01D 29/05 (2006.01), C07D 237/14 (2006.01), C07D 237/16 (2006.01)
Applicants: BRISTOL-MYERS SQUIBB COMPANY [US/US]; P. O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US) (For All Designated States Except US).
SULSKY, Richard [US/US]; (US) (For US Only).
ROBL, Jeffrey, A. [US/US]; (US) (For US Only)
Inventors: SULSKY, Richard; (US).
ROBL, Jeffrey, A.; (US)
Agent: HERMENAU, Ronald; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US)
Priority Data:
60/305,356 13.07.2001 US
Title (EN) PYRAZINONE INHIBITORS OF FATTY ACID BINDING PROTEIN AND METHOD
(FR) INHIBITEURS PYRAZINONES INHIBANT UNE PROTEINE DE LIAISON AUX ACIDES GRAS ET PROCEDE
Abstract: front page image
(EN)aP2 inhibiting compounds are provided having the formula [I] wherein A, X, R and Z are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitors alone or in combination with other therapeutic agents, including other antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.
(FR)L'invention concerne des composés inhibiteurs de protéine aP2 représentés par la formule [I] dans laquelle A, X, R et Z ont la signification indiquée dans la description. L'invention concerne également un procédé de traitement du diabète et des pathologies associées, en particulier le diabète de type II, utilisant de tels inhibiteurs de protéine aP2 seuls ou en combinaison avec d'autres agents thérapeutiques, notamment des agents antidiabétiques tels que la metformine, le glyburide, la troglitazone et/ou l'insuline.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)